Scientists turn a natural cellular process into a drug-delivery system
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
Though the research was intended as a proof of concept, the experimental therapy slowed tumor growth and prolonged survival in mice with gliomas, which constitute about 80 percent of malignant brain tumors in humans.
The technique takes advantage of exosomes, fluid-filled sacs that cells release as a way to communicate with other cells.
While exosomes are gaining ground as biologically friendly carriers of therapeutic materials – because there are a lot of them and they don’t prompt an immune response – the trick with gene therapy is finding a way to fit those comparatively large genetic instructions inside their tiny bodies on a scale that will have a therapeutic effect.
This new method relies on patented technology that prompts donated human cells such as adult stem cells to spit out millions of exosomes that, after being collected and purified, function as nanocarriers containing a drug. When they are injected into the bloodstream, they know exactly where in the body to find their target – even if it’s in the brain.
“Think of them like Christmas gifts: The gift is inside a wrapped container that is postage paid and ready to go,” said senior study author L. James Lee, professor emeritus of chemical and biomolecular engineering at The Ohio State University.
And they are gifts that keep on giving, Lee noted: “This is a Mother Nature-induced therapeutic nanoparticle.”
The study is published today (Dec. 16) in the journal Nature Biomedical Engineering.
In 2017, Lee and colleagues made waves with news of a regenerative medicine discovery called tissue nanotransfection (TNT). The technique uses a nanotechnology-based chip to deliver biological cargo directly into skin, an action that converts adult cells into any cell type of interest for treatment within a patient’s own body.
By looking further into the mechanism behind TNT’s success, scientists in Lee’s lab discovered that exosomes were the secret to delivering regenerative goods to tissue far below the skin’s surface.
The technology was adapted in this study into a technique first author Zhaogang Yang, a former Ohio State postdoctoral researcher now at the University of Texas Southwestern Medical Center, termed cellular nanoporation.
The scientists placed about 1 million donated cells (such as mesenchymal cells collected from human fat) on a nano-engineered silicon wafer and used an electrical stimulus to inject synthetic DNA into the donor cells. As a result of this DNA force-feeding, as Lee described it, the cells need to eject unwanted material as part of DNA transcribed messenger RNA and repair holes that have been poked in their membranes.
“They kill two birds with one stone: They fix the leakage to the cell membrane and dump the garbage out,” Lee said. “The garbage bag they throw out is the exosome. What’s expelled from the cell is our drug.”
The electrical stimulation had a bonus effect of a thousand-fold increase of therapeutic genes in a large number of exosomes released by the cells, a sign that the technology is scalable to produce enough nanoparticles for use in humans.
Essential to any gene therapy, of course, is knowing what genes need to be delivered to fix a medical problem. For this work, the researchers chose to test the results on glioma brain tumors by delivering a gene called PTEN, a cancer-suppressor gene. Mutations of PTEN that turn off that suppression role can allow cancer cells to grow unchecked.
For Lee, founder of Ohio State’s Center for Affordable Nanoengineering of Polymeric Biomedical Devices, producing the gene is the easy part. The synthetic DNA force-fed to donor cells is copied into a new molecule consisting of messenger RNA, which contains the instructions needed to produce a specific protein. Each exosome bubble containing messenger RNA is transformed into a nanoparticle ready for transport, with no blood-brain barrier to worry about.
“The advantage of this is there is no toxicity, nothing to provoke an immune response,” said Lee, also a member of Ohio State’s Comprehensive Cancer Center. “Exosomes go almost everywhere in the body, including passing the blood-brain barrier. Most drugs can’t go to the brain.
“We don’t want the exosomes to go to the wrong place. They’re programmed not only to kill cancer cells, but to know where to go to find the cancer cells. You don’t want to kill the good guys.”
The testing in mice showed the labeled exosomes were far more likely to travel to the brain tumors and slow their growth compared to substances used as controls.
Because of exosomes’ safe access to the brain, Lee said, this drug-delivery system has promise for future applications in neurological diseases such as Alzheimer’s and Parkinson’s disease.
“Hopefully, one day this can be used for medical needs,” Lee said. “We’ve provided the method. If somebody knows what kind of gene combination can cure a certain disease but they need a therapy, here it is.”
Learn more: A new gene therapy strategy, courtesy of Mother Nature
Go deeper with Bing News on:
Gene therapy strategy
- What Lies Ahead? Shaping the Future of Cell and Gene Therapy
Sponsored content brought to you by The launch of Revvity, Inc. in May 2023 signaled the rebranding of an 85-year-old company with a dedicated focus on the diagnostics and life sciences sector.
- Mutant’s partner in crime could be target for future cancer therapy
Defects in RNA processing can promote cancer -- but the mutated proteins responsible can be hard to target. Fred Hutch Cancer Center and Memorial Sloan Kettering Cancer Center scientists discovered a ...
- Pfizer Gains As Gene Therapy Wins FDA Nod
SNAP Beats on Earnings, Shares Rocket Melco Progresses on Sustainability Strategy Report Saia Tumbles on Q1 Results ...
- Buy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy Advancements
Leerink Partners analyst Mani Foroohar maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report) on April 23 and set a ...
- Blocking gene may halt growth of breast cancer cells
"Combining an anti-estrogen therapy with a drug that inhibits PRMT5 could ... tumors resistant to CDK4/6 inhibitors have lost the function of a gene called RB1. Searching for a new strategy to treat ...
Go deeper with Google Headlines on:
Gene therapy strategy
[google_news title=”” keyword=”gene therapy strategy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Therapeutic nanoparticle
- Phosphorex and NOF CORPORATION Collaborate to Supply Lipid Nanoparticle Formulations using NOF's Proprietary Ionizable Lipid, COATSOME® SS Series
Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply ...
- ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of DirectorsCo-Founder of Spark Therapeutics with over 20 years of ...
- ‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’
An experimental medication called CNM-Au8 — a drinkable liquid with gold nanocrystals — has shown promising results in clinical trials for improving MS symptoms. Doctors and researchers weighed in.
- FDA Clears Prime Medicine’s IND for First Prime Editing Therapy
PM359 heads Prime Medicine’s hematology and immunology specialty—one of four therapeutic area specialties or “pillars ... All three apply lipid nanoparticle (LNP) delivery. Ocular—A retinitis ...
- BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
Bristol Myers Squibb’s deal announced Monday will see the pharma pay $65 million upfront to Repertoire Immune Medicines, which will develop autoimmune disease vaccines using its Decode discovery ...
Go deeper with Google Headlines on:
Therapeutic nanoparticle
[google_news title=”” keyword=”therapeutic nanoparticle” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]